**RILUTEK (riluzole)**

Effective Date: 1/28/14  
Date Developed: 1/28/14 by Robert Sterling, MD  
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

*Rilutek* is used in the palliative treatment of amyotrophic lateral sclerosis (ALS) to extend survival and/or time to tracheostomy

**Authorization:** patients diagnosed with ALS

**Dosing:** 50mg every 12 hours, one hour before or two hours after a meal; little or no benefit to increased doses

**PRECAUTIONS:** use with caution in patients with liver disease; neutropenia; hypersensitivity pneumonitis; nausea; abdominal pain; constipation or diarrhea; methemoglobinemia; asthenia

**DRUG INTERACTIONS:** none reported

**REFERENCES**


**Revision History:**

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD  
Date Approved by P&T Committee: 1/27/15  
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/26/16  
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/24/17  
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD  
Date Approved by P&T Committee: 1/23/18  
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

\5:\2020\DRUGS POLICIES\VCHCP
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>